Krystal Biotech, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
CEO Krish S. Krishnan and Chief Accounting Officer Kathryn A. Romano certified the Q2 2026 10-Q (period ended June 30, 2026) as of August 3, 2026, attesting to accuracy of financial statements, effectiveness of disclosure controls, and internal control over financial reporting. No material weaknesses, deficiencies, or control failures reported.
Why this rating
Routine SOX certification exhibits with no disclosed control issues or operational changes. No business, financial, or strategic information provided.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.